Announcement • Jun 23
Hyundai Bioscience Co., Ltd. announced that it has received KRW 10 billion in funding On June 23, 2026, Hyundai Bioscience Co., Ltd. closed the transaction. Announcement • Jun 17
Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 10 billion in funding Hyundai Bioscience Co., Ltd. announced a private placement to issue zero coupon Series 12 Unregistered Unsecured Private Convertible Bonds due June 23, 2029 for gross proceeds of KRW 10,000,000,000 on June 15, 2026. The transaction will include participation from new investors Taurus NXP Private Equity Fund. The transaction has been approved by board of directors, expected to close on June 23, 2026, bears 4% maturity rate, matures on June 23, 2029, 100% convertible into 980,296 shares at a fixed conversion price of KRW 10,201 from June 23, 2027 to May 23, 2029. Announcement • May 23
Hyundai Bioscience Discloses XAFTY IC50 Data for Ebola Hyundai Bioscience announced on May 20th that XAFTY has a strong likelihood of being able to treat Ebola and Hantavirus given its low IC50 (50% inhibitory concentration) for those viruses. The IC50 data is the drug concentration that can inhibit viral replication by 50%. The lower the value, the stronger the antiviral effect with a smaller amount. XAFTY has as IC50 level of 0.28 µM against SARS-CoV-2, the pathogen in COVID-19, and has already proven its therapeutic efficacy in human COVID-19 clinical trials. The IC50 level of XAFTY is even lower for the Ebola virus at 0.125 µM. This suggests that XAFTY could be a promising agent to treat Ebola-infected patients. XAFTY proved its safety through the COVID-19 Phase 2/3 clinical trials and an ongoing Dengue Phase 2/3 clinical trial in Vietnam. No severe adverse events have been reported so far across all dosage groups, reaffirming its clinical safety. Hyundai Bioscience reports that it has enough drug inventory for immediate supply to the outbreak frontlines. XAFTY® has reported on its broad antiviral activity. It demonstrated exceptional inhibitory efficacy of less than 0.125 µM against the Severe Fever with Thrombocytopenia Syndrome (SFTS) virus, which serves as scientific evidence for activity against Hantavirus. Both SFTS virus and Hantavirus belong to the same virus class. 